2025 June 05 | Business Today Qatar

You are here: Home » 2025 » June » Archives for 5th

IBTA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Ibotta, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – IBTA

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial public offering (the “IPO”); or (2) between April 18, 2024 and February 26, 2025, inclusive (the “Class Period”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Ibotta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ibotta class action, go to https://rosenlegal.com/submit–form/?case_id=36526 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, in the Registration Statement and/or throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Ibotta did not properly warn investors of the risk concerning Ibotta’s contract with Kroger; (2) Ibotta’s data measurement system did not provide accurate, precise, and real time client campaign and consumer data measurement; (3) Ibotta’s business mix had shifted and was generating less revenue; and (4) Ibotta had “exhausted” its clients’ budgets, negatively impacting fourth quarter 2024 revenue and expected first quarter 2025 revenue. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ibotta action, go to https://rosenlegal.com/submit–form/?case_id=36526 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com

GLOBENEWSWIRE (Distribution ID 9464232)

Un nouvel agrément signé Denodo récompense le développement rapide d’applications IA

PALO ALTO, Californie, 05 juin 2025 (GLOBE NEWSWIRE) — Denodo, acteur leader de la gestion des données, annonce l’ouverture d’une nouvelle certification, appelée Denodo AI SDK Certified Developer Associate, et destinée à récompenser les professionnels capables d’accélérer le développement de solutions performantes d’intelligence artificielle et d’intelligence artificielle générative, respectivement IA et IAg.

Depuis sa création en novembre 2024, la plateforme 9.1 de Denodo (Denodo Platform 9.1), actuellement disponible en version 9.2 intègre le module Denodo Assistant dédié à l’automatisation des tâches d’ingénierie des données clés en fournissant des éclairages contextualisés et des recommandations intelligentes aux analystes et utilisateurs métier et le module Denodo AI SDK, spécialement conçu pour accélérer le développement d’agents et d’applications alimentés par l’IA.

L’agrément Denodo AI SDK Certified Developer Associate entend permettre aux entreprises d’identifier parmi leur personnel les ressources capables de porter leurs projets Denodo et AI SDK vers de nouveaux sommets en développant des applications d’IA et d’IAg à la fois fiables et exploitables.

« En proposant cette certification, nous ne nous limitons pas à simplifier le développement de l’IA. Nous donnons aux développeurs les clés de l’innovation et de l’excellence nécessaires pour évoluer dans un environnement sujet à de constantes mutations », souligne Alberto Pan, directeur technique chez Denodo. « Cette certification reflète notre engagement en faveur de la promotion de collaborateurs hautement qualifiés et du renforcement de la valeur des solutions IA et IAg. En proposant un parcours concret de valorisation des compétences, nous permettons aux entreprises d’exploiter pleinement leur potentiel en matière d’IA. » poursuit–il.

La maîtrise du module Denodo AI SDK apporte également un avantage compétitif de taille aux développeurs dans un secteur de la gestion des données en pleine croissance. Il va de pair avec la plateforme Denodo pour simplifier et accélérer les processus de développement à l’aide de multiples modèles de langage, ou LLM, configurables et autant de bases vectorielles. Comme il repose sur la technique de génération augmentée de récupération (ou RAG pour Retrieval–Augmented Generation), il facilite l’accès des applications IA aux sources de données fiables de l’entreprise.

Par ailleurs, la certification permet aux développeurs de mettre en avant leurs compétences. Pour José Pallas, récent lauréat d’un agrément Denodo, « Les certifications peuvent véritablement vous aider à sortir du lot, vous exposer à des projets plus complexes et vous permettre d’accéder à des fonctions de leadership. » José Pallas est responsable des données chez Vueling, client de Denodo. Et d’ajouter : « Sans en faire une exigence formelle, Vueling encourage le développement professionnel et sait récompenser la valeur des collaborateurs certifiés. Notre entreprise prend la certification comme le moyen de s’assurer qu’elle emploie les compétences nécessaires en interne pour gérer efficacement son environnement Denodo. »

Hananto Prabowo, expert en données chez Continental et également certifié récemment par Denodo, exprime le même avis sur les possibilités d’évolution de carrière. « Je m’intéresse à la certification, car je souhaite continuer à développer mes compétences et rester au fait dans un univers de la gestion des données en évolution perpétuelle, et ainsi mieux contribuer aux objectifs de mon entreprise. La certification constitue aussi un excellent moyen de réseauter et d’échanger des idées avec d’autres professionnels. »

Les développeurs IA sont invités à s’inscrire dès aujourd’hui pour passer l’examen d’agrément Denodo AI SDK Certified Developer Associate. Pour les aider dans leur parcours de certification, de développement de leurs compétences et accompagner leur réussite dans un monde de plus en plus piloté par l’IA, la Denodo Community met à disposition de nombreuses ressources utiles comme des fiches techniques, des manuels utilisateurs, des tutoriels (dont notamment « comment créer un chatbot IA en quelques minutes »), des articles issus de sa base de données documentaire et des webinaires complets.

Informations supplémentaires

À propos de Denodo
Denodo est un acteur leader de la gestion des données. Sa plateforme primée est une référence en gestion logique des données, transformant les données en informations fiables et en résultats concrets pour toutes les initiatives liées aux données des entreprises, notamment celles axées sur l’IA et le libre–service. Issus de tous les secteurs d’activité à travers le monde, les clients de Denodo ont fourni des données fiables, adaptées à l’IA et aux usages métiers en un tiers du temps habituellement requis, et démontré des performances jusqu’à 10 fois supérieures à celles des architectures de type data lakehouse ou d’autres plateformes classiques. Pour en savoir plus, rendez–vous sur le site Internet denodo.com.

Contacts médias

[email protected]

GLOBENEWSWIRE (Distribution ID 9464313)

ROSEN, A LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm.

SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zenas BioPharma class action, go to https://rosenlegal.com/submit–form/?case_id=37109 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zenas BioPharma action, go to https://rosenlegal.com/submit–form/?case_id=37109 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

GLOBENEWSWIRE (Distribution ID 9464215)

ROSEN, A LEADING LAW FIRM, Encourages NET Power Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NPWR, NPWR.WS

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NET Power Inc. (NYSE: NPWR, NPWR.WS) between June 9, 2023 and March 7, 2025, both dates inclusive (the “Class Period”), of the important June 17, 2025 lead plaintiff deadline.

SO WHAT: If you purchased NET Power securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the NET Power class action, go to https://rosenlegal.com/submit–form/?case_id=38515 call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) NET Power was unlikely to complete Project Permian (NET Power’s efforts to develop its first utility–scale plant) on schedule, and the project was likely to be significantly more expensive than defendants had represented, because of, inter alia, supply chain issues and numerous site– and region–specific challenges; (2) accordingly, defendants’ projections regarding the time and capital needed to complete Project Permian were unrealistic; (3) the increased time and capital needed to complete Project Permian were likely to have a significant negative impact on NET Power’s business and financial results; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

To join the NET Power class action, go to https://rosenlegal.com/submit–form/?case_id=38515 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
www.rosenlegal.com

GLOBENEWSWIRE (Distribution ID 9464217)

TMCI FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Treace Medical class action, go to https://rosenlegal.com/submit–form/?case_id=38284 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the “Lapiplasty”); (2) as a result, Treace Medical’s revenue declined and Treace Medical needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about Treace Medical’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Treace Medical class action, go to https://rosenlegal.com/submit–form/?case_id=38284 call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

GLOBENEWSWIRE (Distribution ID 9464219)

Why the UN Staff Union Does Not Agree with the High Commissioner’s Expensive & Poorly-Managed Project

UN Secretary-General Antonio Guterres briefs reporters on the UN80 Initiative on the restructuring of the world body. Credit: United Nations

By Laura Johnson and Ian Richards
GENEVA, Jun 5 2025 – Like you, we attended last week’s townhall where UN High Commissioner (for Human Rights) Volker Turk presented his latest plans for moving staff out of headquarters. We note that this project has been carried out without adequate consultation with the staff union. The key points we learned and which we are concerned about:

• It’s expensive:

Volker Turk

• It’s mandate is unclear: Volker Turk claims that the General Assembly backed his project. Reading the relevant resolution, it is not clear how he inferred this.

• The justification is questionable: The main reason given was increased demand for OHCHR’s physical presence within countries. We would like to see the letters from governments requesting this. Instead, we hear from you that governments are generally less keen on OHCHR presence, are delaying visas and discouraging meetings on the ground with civil society.

• It’s being rushed unnecessarily: Staff may have mere months to move. One Director told her staff that if they didn’t like it, they could leave, despite the initial management rhetoric of ‘moving posts not people’. We don’t understand the urgency. For UN 80 the current plan is for moves to take place in summer 2026. In addition, if UN 80 results in human rights activities from other entities being merged with OHCHR, new changes might be necessary and such moves might prove premature and unjustified.

• Personal considerations are not taken into account: staff with special constraints have not been listened to, despite this being a key element of the UN’s overall mobility policy. There has been no compendium developed and management has not informed staff on how to contest a move if necessary.

• It copies UNHCR without learning the lessons: UNHCR also expanded regional offices to embellish the organigramme. With the financial crisis, these middle layer offices, neither headquarters nor field, are seen as a luxury, reminiscent of an empire-building past, and are being downsized. Repeating the same mistake at OHCHR carries risks for staff. At the same time OHCHR is a normative entity not an operational one that requires regular mandatory rotation. In the last three years, Volker Turk’s vision appears to have shifted from the former to the latter.

• Questions about conflicts of interest persist: There will be expansion at the Vienna regional field office, which has triggered allegations of favouritism. We have received concerns from you and would appreciate clarification from management on the ethical guardrails used.

We understand that this restructuring will make the careers of some, and we wish them well. But this is being done at huge expense to many on the basis of unclear reasons and objectives that may raise sustainability questions in the future.

Many of you have been in touch about the personal costs these sudden changes will have and the harm you believe it will do to the Office.

In the last few years, human rights around the world have been taking a turn for the worse. We call on Volker Turk and member states to make sure that OHCHR is strengthened rather than being weakened through wasting money, moving staff for the sake of moving, modelling OHCHR after a humanitarian agency, and splashing $12 million on empire-building.

We also call on Volker Turk to treat his staff with the dignity that all human beings deserve in the workplace. This includes hearing each staff member’s concerns with care and attention.

IPS UN Bureau

Excerpt:

Laura Johnson is Executive Secretary and Ian Richards is President of the UN Staff Union in Geneva– in a message to OHCHR staff.

Falcon Elite تسجّل نمواً استثنائياً في حركة طائراتها في أقل من عام واحد

دبي، الإمارات العربية المتحدة،, June 05, 2025 (GLOBE NEWSWIRE) — أعلنت شركة Falcon ، وهي إحدى الشركات ضمن مجموعة Alex Group Investment، عن تسجيلها نمواً استثنائياً بلغ أكثر من 150 في المائة في حركة الطائرات التابعة لأسطولها بين شهر أغسطس من عام 2024 وشهر مايو من عام 2025. يساهم هذا الإنجاز في ترسيخ مكانة الشركة باعتبارها واحدة من أسرع الشركات نمواً في قطاع الطيران الخاص في المنطقة.

خلال أقل من عام واحد، تحوّلت Falcon Elite من محطة طيران واعدة إلى مركز ديناميكي مزدحم تستخدمه نخبة متميزة من العملاء. يساهم هذا الأداء في تسليط الضوء على قدرة Falcon Elite على التنبؤ بفترة الذروة الموسمية التي يختارها العملاء لأسفارهم والاستجابة لها، كما يعكس الثقة التي يوليها العملاء للخدمات الاستثنائية التي تقدمها محطة الطائرات الخاصة.

عند انطلاقها لأول مرة، سجّلت محطة Falcon Elite زيادة متواضعة بلغت 6.92 في المائة في حركة الطائرات. وفي شهر مايو 2025، ارتفعت حركة السفر بشكل ملحوظ لتصل إلى 33.81 في المائة مقارنة بالأشهر السابقة، وهي زيادة مدفوعة باستحواذ الشركة على عملاء جدد، وارتفاع في عدد الرحلات الدبلوماسية، وبداية موسم الصيف.

وكانت المحطة قد سجّلت زيادة بنسبة 52.75 في المائة في حركة الطائرات خلال شهر نوفمبر 2024، بالتزامن مع موسم الذروة في دبي، الذي يشهد مجموعة من الفعاليات والأحداث الكبرى، مثل سباق جائزة أبوظبي الكبرى للفورمولا 1، الذي يعزز الحركة الإقليمية والسفر سواء للعمل أو لقضاء العطلات.

يمثّل هذا النمو نتيجة لسعي الشركة المتواصل لتخطي توقعات العملاء واستغلال الفرص.

وفي هذا السياق، قال السيد Sultan Rashit Abdulla Rashit Al Shene، مؤسس ورئيس مجلس إدارة مجموعة Alex Group Investment: “أود أن أؤكد بأن الأداء المتميز الذي حققناه في Falcon Elite ليس سوى البداية. لقد تمكنا من بناء شركة استثنائية، ويُعزى ذلك إلى الثقة التي وضعها عملاؤنا فينا، إذ أن إيمانهم برؤيتنا شكّل القوة الدافعة وراء نجاحنا.”

لمحة عن شركة Falcon

تُعتبر Falcon مزوّداً رائداً لخدمات الطيران الشاملة، حيث تقدم حلاً متكاملاً يلبي جميع احتياجات العملاء من خدمات الطيران، وكل ذلك ضمن منظومة واحدة متكاملة. لاكتشاف المزيد عن خدماتنا ومنتجاتنا، يمكنكم زيارة موقعنا الإلكتروني الرسمي على الرابط التالي: flyfalcon.com، ومتابعتنا عبر منصات التواصل الاجتماعي “إنستغرام” و“لينكدإن”.

للاستفسارات الإعلامية

Ines Nacerddine
مديرة قسم التسويق – قطاع الطيران
مجموعة Alex Group Investment
البريد الإلكتروني: [email protected]

يمكنكم الاطلاع على الصورة المرفقة بهذا البيان الصحفي عبر الرابط الالكتروني التالي: https://www.globenewswire.com/NewsRoom/AttachmentNg/d1b32af4–08a4–4c31–b315–c5782ce33cca

GLOBENEWSWIRE (Distribution ID 1001101010)

Cellebrite to Acquire Corellium

TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 05, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm–based virtualization software. This combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm–based IoT device. Customers across public safety, defense, intelligence and private sectors will benefit from:

Accelerated identification of mobile vulnerabilities and exploits
Industry–first ability to visualize and interact with virtual devices as if they were physically present – aiding prosecutors, juries, investigators and developers
Increased efficiency, speed and efficacy of DevSecOps across all Arm–based devices
Arm–native and dynamic Mobile Pen Testing

“Leading edge technology matters,” said Thomas E. Hogan, Cellebrite’s interim chief executive officer. “Corellium has built an industry–unique virtualization platform that will ultimately help Cellebrite customers secure both their communities and institutions. The power of this combination goes beyond their technology and includes the addition of some of the brightest minds in vulnerability research, malware analysis and security testing. We could not be more excited about adding the Corellium team to the Cellebrite family. The combination of our respective talent and IP changes the game in the efficient securing and analysis of all Arm–based devices which are pervasive across a vast range of applications from cloud to edge.”

“The combination of Cellebrite’s commitment to innovation and its focus on public safety and security made this the perfect home for our people and our technology,” said Chris Wade, Corellium’s founder and chief technology officer, who will join Cellebrite as chief technology officer. “With Cellebrite’s offerings, users have ‘blueprints’ — technical schematics of what is on a device. With the addition of Corellium’s technology, users will virtually walk through the device, explore every room and open every door safely and without altering a thing in a forensically sound manner. I am personally thrilled to join Tom’s team as the new chief technology officer and to work closely with the Cellebrite research and development team.”

“Arm is the world’s most pervasive computing platform, and as AI continues to transform markets and deliver new experiences, the safety and security of our devices has never been more critical,” said Mohamed Awad, SVP and GM, Infrastructure, Arm. “Corellium's innovative Arm–based virtualization solutions leverage the unique footprint Arm has from cloud to edge, and we value their contributions as part of the ecosystem building the future of computing on Arm.”

The acquisition of Corellium is expected to broaden Cellebrite’s TAM in both the public and private sectors. In the public sector, Corellium’s technology and talent will further enhance and broaden Cellebrite’s Digital Investigation Platform, while Corellium’s solution for mobile vulnerability research is expected to increase Cellebrite’s offerings for customers in the defense and intelligence sector. In the private sector, Corellium’s virtualization platform is expected to extend Cellebrite’s reach beyond eDiscovery and corporate investigation use cases through powerful virtualization solutions that enable development and security professionals to design the next generation of high–performance, secure mobile applications, IoT devices and automotive systems.

Cellebrite intends to acquire Corellium for an enterprise value of $170 million in cash with $20 million converted to equity at closing. Corellium securityholders will receive up to an additional $30 million in cash based on the achievement of certain performance milestones over the next two years. The deal is expected to close this summer, subject to approval of the Committee on Foreign Investment in the United States and other customary closing conditions. Cellebrite plans to provide additional information about Corellium’s anticipated financial contribution after the transaction closes.

J.P. Morgan Securities LLC is acting as exclusive financial advisor to Corellium.

Finally, Cellebrite is approaching the conclusion of its thorough CEO search process. The Company expects and plans to announce the appointment of the permanent CEO in conjunction with or prior to the mid–August disclosure of its second quarter 2025 results.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite’s AI–powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite’s digital forensic and investigative solutions—available via cloud, on–premises, and hybrid deployments—to close cases faster and safeguard communities. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com, and find us on social media @Cellebrite.

About Corellium
Corellium is the leader in Arm hypervisor virtualization, helping security and developer teams build, test, and secure software for mobile, automotive, and IoT devices using the power of virtual hardware. Over 500 organizations, governments, and security practitioners worldwide rely on Corellium’s virtualization solutions to enhance security testing and streamline DevOps. By providing highly performant, scalable, and precise virtual models, Corellium enables new capabilities not possible with physical hardware. Corellium previously raised $25M in a Series A round, led by Paladin Capital Group with participation from Cisco Investments.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, this combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm–based IoT device; with the addition of Corellium’s technology, users will virtually walk through the device, explore every room and open every door safely and without altering a thing in a forensically sound manner; Chris Wade’s prospective appointment as chief technology officer; the acquisition of Corellium is expected to broaden Cellebrite’s TAM in both the public and private sectors; in the public sector, Corellium’s technology and talent will further enhance and broaden Cellebrite’s digital forensics capabilities while Corellium’s solution for mobile vulnerability research is expected to increase Cellebrite’s offerings for customers in the defense and intelligence sector; in the private sector, Corellium’s virtualization platform is expected to extend Cellebrite’s reach beyond eDiscovery and corporate investigation use cases through powerful virtualization solutions that enable development and security professionals to design the next generation of high–performance, secure mobile applications, IoT devices and automotive systems; the timing associated with closing the transaction; Corellium earning up to an additional $30M in cash based on the achievement of certain performance milestones over the next two years; and the potential impact of the transaction on the Company’s 2025 revenue, annual recurring revenue (ARR), adjusted EBITDA, operating profitability and earnings are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on April 27, 2023 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media
Jackie Labrecque
Sr. Manager of Content Strategy and Operations
[email protected]
+1 771.241.7010

Investor Relations
Andrew Kramer
Vice President, Investor Relations
[email protected]
+1 973.206.7760

GLOBENEWSWIRE (Distribution ID 9463719)

LyondellBasell conclut un accord et entame des négociations exclusives avec AEQUITA pour la vente de quatre actifs issus de son évaluation stratégique européenne

ROTTERDAM, Pays–Bas, 05 juin 2025 (GLOBE NEWSWIRE) — LyondellBasell (LYB) a annoncé aujourd’hui avoir conclu un accord et entamé des négociations exclusives avec AEQUITA pour la vente de certains actifs oléfines et polyoléfines et les activités associées en Europe. Les sites concernés font partie de l’évaluation stratégique européenne précédemment annoncée et sont situés à Berre (France), Münchsmünster (Allemagne), Carrington (Royaume–Uni) et Tarragone (Espagne).

« Cette transaction envisagée constitue une étape importante dans la transformation de LYB pour renforcer et moderniser notre cœur de métier. Nous nous engageons à exploiter nos actifs de manière sûre et fiable tout au long de ce processus et continuerons à soutenir nos clients, salariés et autres parties prenantes clés », a déclaré Peter Vanacker, Président–Directeur Général de LyondellBasell. « L’Europe reste un marché clé pour LYB sur lequel nous continuerons à opérer après cette transaction, en nous concentrant davantage sur la création de valeur, en établissant notamment une position de leadership rentable dans les solutions circulaires et renouvelables. »

Les actifs et les activités faisant l’objet du rachat par AEQUITA comprennent des sites intégrés et non intégrés au sein de l’activité européenne des oléfines et polyoléfines de LyondellBasell, ainsi que des fonctions support basées au siège social de la Société à Rotterdam et dans diverses autres localisations. Ces sites représentent collectivement une vaste plateforme d’oléfines et de polyoléfines située stratégiquement à proximité d’une clientèle de longue date et bénéficiant d’un accès et d’une connexion à des infrastructures clés.

« L'acquisition de ces actifs de LYB marque une nouvelle étape importante dans l'expansion de notre empreinte industrielle », a déclaré Christoph Himmel, Managing Partner chez AEQUITA. « Chaque site apporte une base opérationnelle solide et un personnel hautement expérimenté et engagé. Nous sommes confiants dans notre capacité à accélérer leur développement grâce au modèle de gestion d'AEQUITA. Nous sommes impatients d'accueillir les équipes dans notre Groupe et de travailler en collaboration avec toutes les parties prenantes, pour assurer une transition en douceur et mettre en place une plateforme robuste pour un succès à long terme. »

L’accord conclu entre LyondellBasell et AEQUITA prend la forme d’un contrat d’option de vente en vertu duquel AEQUITA s’engage à conclure un contrat d’achat type convenu, si LyondellBasell exerce son option de vente, une fois les procédures de consultations des comités d’entreprises achevées.

La clôture de la transaction envisagée est actuellement prévue au cours du premier semestre 2026, sous réserve de l’achèvement des processus d’information et de consultation avec les organismes représentatifs du personnel concernés conformément aux lois en vigueur, et aux conditions de clôture réglementaires et autres conditions habituelles. Citi et J.P. Morgan sont intervenus en tant que conseillers financiers et Linklaters LLP en tant que conseiller juridique de LyondellBasell.

Conférence téléphonique avec les investisseurs

LYB organisera une conférence téléphonique le 5 juin à 8 h 00 EDT. Les participants à la conférence téléphonique comprendront le Président–Directeur Général Peter Vanacker, le Directeur Financier Agustin Izquierdo, le Vice–Président Exécutif de Global Olefins and Polyolefins and Refining Kim Foley et le Directeur des Relations avec les Investisseurs Dave Kinney.

Le numéro d’appel gratuit aux États–Unis est le 1–877–407–8029 et le 201–689–8029 en dehors des États–Unis ou en cliquant sur le lien CallMe.

Les diapositives qui accompagnent la conférence téléphonique seront disponibles sur https://investors.lyondellbasell.com/events–and–presentations/.

Un enregistrement de la conférence téléphonique sera disponible le 5 juin à partir de 13 h EDT jusqu’au 5 juillet. Les numéros pour réécouter la conférence téléphonique sont le +1 (877) 660–6853 (États–Unis) et le 201–612–7415 (payant). Le code d’accès pour chaque numéro est le 13754240.

À propos de LyondellBasell

Nous sommes LyondellBasell (NYSE : LYB), un leader de l’industrie chimique mondiale qui crée des solutions pour un mode de vie durable au quotidien. Grâce à une technologie de pointe et à des investissements ciblés, nous œuvrons pour une économie circulaire à faible émission de carbone. Dans l'ensemble de nos activités, nous cherchons à créer de la valeur pour nos clients, nos investisseurs et la société. En tant que grand producteur mondial de polymères et leader des technologies des polyoléfines, nous développons, fabriquons et commercialisons des produits innovants et de qualité supérieure pour des applications variées allant du transport durable à la sécurité alimentaire, en passant par l’eau potable et les soins de santé qualitatifs. Pour en savoir plus, consultez le site www.lyondellbasell.com ou suivez @LyondellBasell sur LinkedIn.

À propos d’AEQUITA

AEQUITA est un groupe industriel basé à Munich qui investit dans des situations particulières, notamment des scissions d'entreprises, des successions et des transformations en Europe. Son portefeuille actuel génère plus de 3,5 milliards d'euros de chiffre d'affaires. Fort d'une solide assise financière, d'une expertise entrepreneuriale et d'une approche partenariale, AEQUITA se concentre sur l'acquisition et la valorisation à long terme d'entreprises susceptibles de bénéficier de son engagement opérationnel. Pour plus d'informations, rendez–vous sur www.aequita.com.

Requêtes médias LYB Global
Relations avec les médias LyondellBasell
Téléphone :+1–713–309–7575
E–mail :[email protected]

Ou :

Requêtes médias LYB Europe
Robert Kleissen, Affaires extérieures Europe
Téléphone : +31–6–273–573–98
E–mail :[email protected]

Requêtes médias AEQUITA

Simon Schulz, Partner

Téléphone: +49–89–2620–4840–0

Email: [email protected]

Déclarations prospectives LYB
Les déclarations contenues dans le présent communiqué concernant des faits qui ne sont pas historiques sont des déclarations prospectives. Les résultats réels pourraient différer sensiblement en raison de différents facteurs, notamment notre capacité à aligner notre base d'actifs avec nos objectifs stratégiques, notre capacité à mener à bien les transactions envisagées par l'option de vente et les accords connexes, l'achèvement des processus d'information et de consultation des organes de représentation des salariés concernés, et la satisfaction des conditions réglementaires et autres conditions de clôture habituelles. D’autres facteurs susceptibles de faire varier sensiblement les résultats par rapport à ceux décrits dans les déclarations prospectives sont disponibles dans la rubrique « Facteurs de risque » de notre Formulaire 10–K pour l’exercice clos le 31 décembre 2024, disponible à l’adresse www.LyondellBasell.com sur la page Relations avec les investisseurs et sur le site Web de la Securities and Exchange Commission à l’adresse www.sec.gov. Rien ne garantit que les actes, événements ou résultats des déclarations prospectives se produiront, ou si tel est le cas pour l’un d’entre eux, quel sera leur impact sur nos résultats d’exploitation ou notre situation financière. Les déclarations prospectives ne valent qu’à la date à laquelle elles ont été faites et sont basées sur les estimations et les opinions de la direction de LyondellBasell à cette date. LyondellBasell exclut toute obligation de mettre à jour les déclarations prospectives en cas d’évolution de la situation ou de changement des estimations ou opinions de la direction, à moins que la loi ne l’impose.

GLOBENEWSWIRE (Distribution ID 9463782)

LyondellBasell tritt in eine Vereinbarung und exklusive Verhandlungen mit AEQUITA über den Verkauf von vier europäischen Vermögenswerten im Rahmen der strategischen Bewertung ein

ROTTERDAM, Niederlande, June 05, 2025 (GLOBE NEWSWIRE) — LyondellBasell (LYB) gab heute bekannt, dass das Unternehmen eine Vereinbarung eingegangen ist und exklusive Verhandlungen mit AEQUITA über den Verkauf ausgewählter Vermögenswerte aus dem Olefine– & Polyolefinbereich und des damit verbundenen Geschäfts in Europa aufgenommen hat. Die zu veräußernden Standorte waren Teil der zuvor angekündigten europäischen strategischen Bewertung und befinden sich in Berre (Frankreich), Münchsmünster (Deutschland), Carrington (Großbritannien) und Tarragona (Spanien).

„Diese geplante Transaktion ist ein bedeutender Schritt im Rahmen der Transformation von LYB, um unser Kerngeschäft zu erweitern und zu verbessern. Wir verpflichten uns, unsere Anlagen während dieses Prozesses sicher und zuverlässig zu betreiben und werden unsere Kunden, Mitarbeiter und andere wichtige Stakeholder weiterhin unterstützen“, sagte Peter Vanacker, Chief Executive Officer von LyondellBasell. „Europa bleibt ein Kernmarkt für LYB, auf dem wir auch nach dieser Transaktion weiter aktiv sein werden, wobei wir uns stärker auf die Wertschöpfung durch den Aufbau einer profitablen Führungsposition bei Kreislauflösungen und erneuerbaren Energien konzentrieren werden.“

Zu den Anlagen und Geschäftsbereichen, die von AEQUITA übernommen werden sollen, gehören integrierte und nicht integrierte Standorte des europäischen Olefin– und Polyolefingeschäfts von LyondellBasell sowie unterstützende zentrale Funktionen am Hauptsitz des Unternehmens in Rotterdam und an verschiedenen anderen Standorten. Die Standorte bilden zusammen eine skalierte Plattform für Olefine und Polyolefine, die strategisch günstig in der Nähe eines langjährigen Kundenstamms liegt und Zugang zu wichtigen Infrastrukturen und deren Anbindung bietet.

„Der Erwerb dieser Vermögenswerte von LYB stellt einen weiteren wichtigen Schritt zur Erweiterung unserer industriellen Präsenz dar“, sagte Christoph Himmel, geschäftsführender Gesellschafter bei AEQUITA. „Jeder Standort bringt eine starke operative Basis sowie ein hochqualifiziertes und engagiertes Mitarbeiterteam mit. Wir sind zuversichtlich, dass wir ihre Entwicklung unter dem Eigentümeransatz von AEQUITA beschleunigen können. Wir freuen uns darauf, die Teams in unserer Gruppe willkommen zu heißen und gemeinsam mit allen Beteiligten an einem reibungslosen Übergang und dem Aufbau einer starken Plattform für langfristigen Erfolg zu arbeiten.“

Die Vereinbarung zwischen LyondellBasell und AEQUITA ist eine Verkaufsoptionsurkunde, in der sich AEQUITA verpflichtet hat, einen im Voraus abgestimmten Kaufvertrag abzuschließen, falls LyondellBasell seine Verkaufsoption ausübt – und zwar nach Abschluss bestimmter Konsultationsverfahren mit dem Betriebsrat.

Der Vollzug der vorgeschlagenen Transaktion wird derzeit in der ersten Hälfte des Jahres 2026 erwartet, vorbehaltlich des Abschlusses der Informations– und Konsultationsprozesse mit den zuständigen Arbeitnehmervertretungen gemäß den geltenden Gesetzen sowie der Erfüllung der regulatorischen und sonstigen üblichen Vollzugsbedingungen. Citi und J.P. Morgan Securities LLC waren als Finanzberater und Linklaters LLP als Rechtsberater von LyondellBasell tätig.

Telefonkonferenz für Investoren

LYB wird am 5. Juni um 8.00 Uhr EDT eine Telefonkonferenz abhalten. An der Telefonkonferenz werden Chief Executive Officer Peter Vanacker, Chief Financial Officer Agustin Izquierdo, Executive Vice President of Global Olefins and Polyolefins and Refining Kim Foley und Head of Investor Relations Dave Kinney teilnehmen.

Die gebührenfreie Einwahlnummer in den USA lautet 877–660–6853 und 201 689–8029 außerhalb der USA oder CallMe link.

Die Folien zu dieser Telefonkonferenz sind unter https://investors.lyondellbasell.com/events–and–presentations/ verfügbar.

Eine Aufzeichnung der Telefonkonferenz wird von Donnerstag, den 5. Juni um 13:00 Uhr EDT bis 5. Juli verfügbar sein. Die Einwahlnummern für die Aufzeichnung sind +1 (877) 660–6853 (USA) und +1 (201) 612–7415 (gebührenpflichtig). Der Passcode für beide Nummern lautet 13754240.

Über LyondellBasell

Wir sind LyondellBasell – ein führendes Unternehmen der globalen Chemieindustrie, das Lösungen für ein nachhaltiges Leben im Alltag entwickelt. Durch fortschrittliche Technologien und gezielte Investitionen ermöglichen wir eine kreislauforientierte und kohlenstoffarme Wirtschaft. Bei allem, was wir tun, sind wir bestrebt, Werte für unsere Kunden, Investoren und die Gesellschaft zu schaffen. Als einer der weltweit größten Hersteller von Polymeren und führend in der Polyolefintechnologie entwickeln, produzieren und vermarkten wir hochwertige und innovative Produkte für Anwendungen, die von nachhaltigem Transport und Lebensmittelsicherheit bis hin zu sauberem Wasser und hochwertiger Gesundheitsversorgung reichen. Weitere Informationen finden Sie unter www.lyondellbasell.com oder folgen Sie @LyondellBasell auf LinkedIn.

Über AEQUITA
AEQUITA ist eine in München ansässige Industriegruppe, die in Sondersituationen investiert – darunter Unternehmensausgliederungen, Nachfolgeregelungen und Transformationen in ganz Europa. Das aktuelle Portfolio erwirtschaftet einen Umsatz von über 3,5 Milliarden Euro. Mit einer starken Kapitalbasis, unternehmerischem Know–how und einem partnerschaftlichen Ansatz konzentriert sich AEQUITA auf den Erwerb und die langfristige Wertsteigerung von Unternehmen, die von ihrem operativen Engagement profitieren können.
Weitere Informationen finden Sie unter www.aequita.com.

Medienanfragen LYB Global
LyondellBasell Media Relations
Telefon: +1–713–309–7575
E–Mail: [email protected]

Oder:

Medienanfragen LYB Europa
Robert Kleissen, External Affairs Europe
Telefon: +31–6–273–573–98
E–Mail: [email protected]

Medienanfragen
Simon Schulz, Partner
Telefon: +49–89–2620–4840–0
Email: [email protected]

Zukunftsgerichtete Aussagen LYB
Die Aussagen in dieser Mitteilung, die sich auf Angelegenheiten beziehen, die keine historischen Fakten darstellen, sind zukunftsgerichtete Aussagen. Die tatsächlichen Ergebnisse können erheblich abweichen, was unter anderem davon abhängt, ob wir in der Lage sind, unsere Assets mit unseren strategischen Zielen in Einklang zu bringen, ob wir in der Lage sind, die in der Put–Option und den damit verbundenen Vereinbarungen vorgesehenen Transaktionen erfolgreich abzuschließen, ob die Informations– und Konsultationsprozesse der zuständigen Arbeitnehmervertretungen abgeschlossen sind und ob die regulatorischen und sonstigen üblichen Abschlussbedingungen erfüllt sind. Weitere Faktoren, die dazu führen könnten, dass die Ergebnisse wesentlich von den in den zukunftsgerichteten Aussagen beschriebenen abweichen, finden Sie im Abschnitt „Risk Factors“ in unserem Formular 10–K für das am 31. Dezember 2024 abgeschlossene Geschäftsjahr, das Sie unter www.LyondellBasell.com auf der Seite Investor Relations und auf der Website der Securities and Exchange Commission unter www.sec.gov finden. Es gibt keine Garantie dafür, dass die in den zukunftsgerichteten Aussagen genannten Handlungen, Ereignisse oder Ergebnisse eintreten werden, und welche Auswirkungen sie auf unsere Betriebsergebnisse oder unsere Finanzlage haben werden, falls sie eintreten sollten. Zukunftsgerichtete Aussagen beziehen sich nur auf das Datum, an dem sie gemacht wurden, und basieren auf den Einschätzungen und Meinungen des Managements von LyondellBasell zum Zeitpunkt dieser Aussagen. LyondellBasell übernimmt keine Verpflichtung, zukunftsgerichtete Aussagen zu aktualisieren, falls sich die Umstände oder die Einschätzungen oder Meinungen des Managements ändern, es sei denn, dies ist gesetzlich vorgeschrieben.

GLOBENEWSWIRE (Distribution ID 9463782)